223 related articles for article (PubMed ID: 30683265)
21. Genetic risk assessment in breast and gynecologic malignancies- what's to know in 2024?
Kamara D; Silver E; Niell-Swiller M
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):45-50. PubMed ID: 37792522
[TBL] [Abstract][Full Text] [Related]
22. Screening and prevention of hereditary gynecologic cancers.
Kehoe SM; Kauff ND
Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
[TBL] [Abstract][Full Text] [Related]
23. Tumor genome analysis includes germline genome: are we ready for surprises?
Catenacci DV; Amico AL; Nielsen SM; Geynisman DM; Rambo B; Carey GB; Gulden C; Fackenthal J; Marsh RD; Kindler HL; Olopade OI
Int J Cancer; 2015 Apr; 136(7):1559-67. PubMed ID: 25123297
[TBL] [Abstract][Full Text] [Related]
24. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.
Johnson LM; Valdez JM; Quinn EA; Sykes AD; McGee RB; Nuccio R; Hines-Dowell SJ; Baker JN; Kesserwan C; Nichols KE; Mandrell BN
Cancer; 2017 Jun; 123(12):2352-2359. PubMed ID: 28192596
[TBL] [Abstract][Full Text] [Related]
25. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
26. Genetic risk assessment for breast and gynecological malignancies.
Profato JL; Arun BK
Curr Opin Obstet Gynecol; 2015 Feb; 27(1):1-5. PubMed ID: 25502427
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Based Genetic Testing and Familial Cancer Risk.
Forman A; Sotelo J
Cold Spring Harb Perspect Med; 2020 Aug; 10(8):. PubMed ID: 31570381
[TBL] [Abstract][Full Text] [Related]
28. The role of genetic testing for cancer susceptibility in gynecologic practice.
Karlan BY; Berchuck A; Mutch D
Obstet Gynecol; 2007 Jul; 110(1):155-67. PubMed ID: 17601911
[TBL] [Abstract][Full Text] [Related]
29. Genetics of gynaecological cancers.
Constantinou P; Tischkowitz M
Best Pract Res Clin Obstet Gynaecol; 2017 Jul; 42():114-124. PubMed ID: 28202331
[TBL] [Abstract][Full Text] [Related]
30. Screening for gynaecologic cancers in genetically predisposed women.
Dreyer G
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):267-82. PubMed ID: 22361688
[TBL] [Abstract][Full Text] [Related]
31. Lynch Syndrome Screening in the Gynecologic Tract: Current State of the Art.
Mills AM; Longacre TA
Am J Surg Pathol; 2016 Apr; 40(4):e35-44. PubMed ID: 26872009
[TBL] [Abstract][Full Text] [Related]
32. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
33. Early detection and risk reduction for familial gynecologic cancers.
Chen LM; Karlan BY
Clin Obstet Gynecol; 1998 Mar; 41(1):200-14. PubMed ID: 9504236
[No Abstract] [Full Text] [Related]
34. ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.
Obstet Gynecol; 2018 Jan; 131(1):194-195. PubMed ID: 29266071
[TBL] [Abstract][Full Text] [Related]
35. Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
Griffin NE; Buchanan TR; Smith SH; Leon AA; Meyer MF; Liu J; Tabak RG; Fuh KC; Thaker PH; Powell MA; Mutch DG; Massad LS; Colditz GA; Hagemann AR
Gynecol Oncol; 2020 Jan; 156(1):140-146. PubMed ID: 31780235
[TBL] [Abstract][Full Text] [Related]
36. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.
Al-Shinnag M; Cheong PL; Goodwin A; Trent R; Yu B
Pathology; 2024 Jun; 56(4):468-472. PubMed ID: 38627125
[TBL] [Abstract][Full Text] [Related]
37. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
[TBL] [Abstract][Full Text] [Related]
38. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
Ferguson SE; Aronson M; Pollett A; Eiriksson LR; Oza AM; Gallinger S; Lerner-Ellis J; Alvandi Z; Bernardini MQ; MacKay HJ; Mojtahedi G; Tone AA; Massey C; Clarke BA
Cancer; 2014 Dec; 120(24):3932-9. PubMed ID: 25081409
[TBL] [Abstract][Full Text] [Related]
39. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
[TBL] [Abstract][Full Text] [Related]
40. Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
Cheng H; Powers J; Schaffer K; Sartor O
Am Soc Clin Oncol Educ Book; 2018 May; 38():372-381. PubMed ID: 30231311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
